Recent Advances in the Development of Selective CB2 Agonists as Promising Anti-Inflammatory Agents

Author(s): N. Leleu-Chavain, M. Body-Malapel, J. Spencer, P. Chavatte, P. Desreumaux, R. Millet

Journal Name: Current Medicinal Chemistry

Volume 19 , Issue 21 , 2012

Become EABM
Become Reviewer


The high distribution of CB2 receptors in immune cells suggests their important role in the control of inflammation. Growing evidence offers this receptor as an attractive therapeutic target: CB2 selective agonists are able to modulate inflammation without triggering psychotropic effects. This review will summarize the literature on the implication of CB2 in inflammation and CB2 selective agonists with anti-inflammatory activity.

Keywords: cannabinoids, CB2 receptors, CB2 agonists, inflammation, anti-inflammatory agents, central nervous system inflammation, chronic inflammatory diseases, IBD, Crohn’s disease, ulcerative colitis, ischemia/reperfusion injury, aminoalkylindoles, tricyclic pyrazoles, morpholines, quinolones

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [3457 - 3474]
Pages: 18
DOI: 10.2174/092986712801323207
Price: $65

Article Metrics

PDF: 21